AIM: To evaluate the impact of heat-shock protein 90 (HSP90) blockade by the novel inhibitor NVP-AUY922, on tumor growth and angiogenesis in pancreatic cancer. MATERIALS AND METHODS: Effects of NVP-AUY922 on signaling pathways were evaluated by western blotting. Cell motility of cancer cells, pericytes and endothelial cells was investigated in Boyden chambers. Impact of HSP90 blockade on pancreatic tumor growth and angiogenesis were studied in in vivo tumor models. RESULTS: NVP-AUY922 effectively inhibited cancer cell growth. Moreover, HSP90 inhibition potently interfered with multiple signaling pathways in cancer cells, as well as endothelial cells and pericytes, leading to significant reduction of pro-migratory and invasive properties of these cell types. In vivo, treatment with NVP-AUY922 significantly inhibited growth and vascularization of pancreatic cancer at doses far below the maximum tolerated dose. CONCLUSION: HSP90 blockade by the novel synthetic inhibitor NVP-AUY922 effectively reduces pancreatic cancer progression through direct effects on cancer cells, as well as on endothelial cells and pericytes.
AIM: To evaluate the impact of heat-shock protein 90 (HSP90) blockade by the novel inhibitor NVP-AUY922, on tumor growth and angiogenesis in pancreatic cancer. MATERIALS AND METHODS: Effects of NVP-AUY922 on signaling pathways were evaluated by western blotting. Cell motility of cancer cells, pericytes and endothelial cells was investigated in Boyden chambers. Impact of HSP90 blockade on pancreatic tumor growth and angiogenesis were studied in in vivo tumor models. RESULTS: NVP-AUY922 effectively inhibited cancer cell growth. Moreover, HSP90 inhibition potently interfered with multiple signaling pathways in cancer cells, as well as endothelial cells and pericytes, leading to significant reduction of pro-migratory and invasive properties of these cell types. In vivo, treatment with NVP-AUY922 significantly inhibited growth and vascularization of pancreatic cancer at doses far below the maximum tolerated dose. CONCLUSION:HSP90 blockade by the novel synthetic inhibitor NVP-AUY922 effectively reduces pancreatic cancer progression through direct effects on cancer cells, as well as on endothelial cells and pericytes.
Authors: Amanda J Walker; Sara R Alcorn; Amol K Narang; Katriana M Nugent; Aaron T Wild; Joseph M Herman; Phuoc T Tran Journal: Curr Probl Cancer Date: 2013-10-05 Impact factor: 3.187
Authors: Nishant Gandhi; Aaron T Wild; Sivarajan T Chettiar; Khaled Aziz; Yoshinori Kato; Rajendra P Gajula; Russell D Williams; Jessica A Cades; Anvesh Annadanam; Danny Song; Yonggang Zhang; Russell K Hales; Joseph M Herman; Elwood Armour; Theodore L DeWeese; Edward M Schaeffer; Phuoc T Tran Journal: Cancer Biol Ther Date: 2013-01-28 Impact factor: 4.742
Authors: Annerleim Walton-Diaz; Sahar Khan; Dimitra Bourboulia; Jane B Trepel; Len Neckers; Mehdi Mollapour Journal: Future Med Chem Date: 2013-06 Impact factor: 3.808
Authors: Yuchen Zhang; Michael B Ware; Mohammad Y Zaidi; Amanda N Ruggieri; Brian M Olson; Hannah Komar; Matthew R Farren; Ganji Purnachandra Nagaraju; Chao Zhang; Zhengjia Chen; Juan M Sarmiento; Rafi Ahmed; Shishir K Maithel; Bassel F El-Rayes; Gregory B Lesinski Journal: Mol Cancer Ther Date: 2020-10-09 Impact factor: 6.009